Advances In™ Hematology: How Can We Translate Recent Evidence Into the Clinical Management of High-Risk MDS?

Advances In™ Hematology: How Can We Translate Recent Evidence Into the Clinical Management of High-Risk MDS? is organized by Physicians' Education Resource, LLC (PER).

Release Date: August 30, 2019
Expiration Date: August 30, 2020

Target Audience:
This activity is intended for medical oncologists, hematologists, and other oncology healthcare professionals interested in the latest advances in the treatment of patients with MDS. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the treatment of MDS are also invited to attend.

Accreditation/Credit Designation:
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Activity Overview:
Accurate and rapid diagnosis and classification of myelodysplastic syndromes (MDS) subtype is critical to initiate effective treatment for patients who are at high risk of disease progression. Risk stratification systems enable clinicians to categorize the level of risk for each patient and further determine best therapeutic options for patients with high-risk MDS. It is paramount that healthcare providers remain current in their knowledge of clinical data that support or refute therapeutic options that are US Food and Drug Administration (FDA)?approved or in clinical development. Recent reports from clinical trial data offer potential for changes to the treatment of high-risk MDS that need to be incorporated into the decision-making process, as well as into strategies for management of anemia and low platelet count. It is also extremely important that clinicians who treat patients with MDS are aware of ongoing clinical trials to refer patients for enrollment, when appropriate, for the best clinical outcomes.

This Advances In: Hematology program will help clinicians meet the challenge of acquiring this knowledge by featuring a series of video interviews with top experts in MDS addressing making an accurate diagnosis of MDS, best practices in risk stratification of patients with MDS, and how clinical challenges that are commonly observed can be overcome in patients with high-risk MDS, as well as reviewing novel therapeutic options for this high-risk patient population.

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Describe the current categorization of MDS disease and how risk stratification impacts clinical decision-making
• Summarize evidence-based diagnostic and therapeutic strategies for the treatment of MDS
• Assess how individual patient characteristics can impact outcomes in MDS, including response to therapies, survival, or progression to AML
• Define the role of new and emerging therapies and their clinical applications to the future of MDS management.